Bavarian Nordic (OTCMKTS:BVNRY) Trading Up 4% – Should You Buy?

Bavarian Nordic (OTCMKTS:BVNRY)’s share price traded up 4% during trading on Thursday . The company traded as high as $11.1150 and last traded at $11.1150. Approximately 510 shares changed hands during trading, a decline of 84% from the average daily volume of 3,230 shares. The stock had previously closed at $10.69.

Bavarian Nordic Stock Performance

The company has a market capitalization of $2.66 billion, a PE ratio of 11.29 and a beta of 1.20. The stock’s fifty day simple moving average is $10.04 and its 200-day simple moving average is $9.81.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings results on Friday, August 21st. The company reported $0.46 EPS for the quarter. The business had revenue of $316.47 million during the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.

About Bavarian Nordic

Bavarian Nordic A/S (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and commercializes vaccines for infectious diseases. The company serves government agencies, military organizations, healthcare providers and travelers, with products distributed across Europe, North America and other international markets.

Its best-known product is JYNNEOS, also marketed as IMVAMUNE or IMVANEX in certain regions, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for rabies and tick-borne encephalitis, including RabAvert and Rabipur for rabies prevention and Encepur for protection against tick-borne encephalitis.